A freeze on tailored antiplatelet therapy?
From the Department of Medicine, Center for Personalized and Precision Medicine, Duke University, Durham, NC (D.V.); and Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.). deepak.voora@duke.edu.
Deepak
D
Voora
From the Department of Medicine, Center for Personalized and Precision Medicine, Duke University, Durham, NC (D.V.); and Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.).
Richard C
RC
Becker
D003324:Coronary Artery Disease / Q000517:prevention & control*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D015539:Platelet Activation / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D055502:Secondary Prevention / Q000379:methods*
D010975:Platelet Aggregation Inhibitors
Editorials; individualized medicine; platelet aggregation; platelet aggregation inhibitors